Patent ID: 9572831
Date: 2017-02-21
CPC Classifications: A61K

Claim:
1. A nanoformulation, comprising: nanoparticles, each nanoparticle comprising a shell within which a glycosaminoglycan (GAG) is encapsulated, said GAG being ionically or covalently bonded to the shell, wherein the GAG is selected from the group consisting of sulfated non-anticoagulant heparin (SNACH), super-sulfated non-anticoagulant heparin (S-SNACH), and a combination thereof, and wherein the shell comprises Poly(lactic-co-glycolic acid) (PLGA), Polyethylene Glycol (PEG)-PLGA, maleimide-PEG-PLGA,chitosan, chitosan-PLGA, a blend of methoxy-polyethyleneglycol-poly(lactide-co-glycolide)(MPEG-PLGA) and maleimide-PEG-PLGA, or calcium alginate, wherein the nanoparticles are conjugated to Poly L-arginine via an amide link between the GAG and the Poly L-arginine, wherein the shell encapsulates a chemotherapeutic agent for treating cancer, and wherein a targeted moiety is conjugated to the shell of the nanoparticle to effectuate a targeted delivery of the nanoparticle to a specified target for increasing the efficacy of the chemotherapeutic agent.